228 related articles for article (PubMed ID: 12358061)
1. Impact of meningococcal C conjugate vaccine in the UK.
Balmer P; Borrow R; Miller E
J Med Microbiol; 2002 Sep; 51(9):717-722. PubMed ID: 12358061
[TBL] [Abstract][Full Text] [Related]
2. Limited Impact of Adolescent Meningococcal ACWY Vaccination on Neisseria meningitidis Serogroup W Carriage in University Students.
Oldfield NJ; Green LR; Parkhill J; Bayliss CD; Turner DPJ
J Infect Dis; 2018 Jan; 217(4):608-616. PubMed ID: 29155998
[TBL] [Abstract][Full Text] [Related]
3. Prospects for vaccine prevention of meningococcal infection.
Harrison LH
Clin Microbiol Rev; 2006 Jan; 19(1):142-64. PubMed ID: 16418528
[TBL] [Abstract][Full Text] [Related]
4. Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.
de Waure C; Miglietta A; Nedovic D; Mereu G; Ricciardi W
Hum Vaccin Immunother; 2016; 12(2):467-73. PubMed ID: 26308192
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.
Lawrence GL; Wang H; Lahra M; Booy R; McINTYRE PB
Epidemiol Infect; 2016 Aug; 144(11):2382-91. PubMed ID: 27094814
[TBL] [Abstract][Full Text] [Related]
6. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.
Maiden MC; Ibarz-Pavón AB; Urwin R; Gray SJ; Andrews NJ; Clarke SC; Walker AM; Evans MR; Kroll JS; Neal KR; Ala'aldeen DA; Crook DW; Cann K; Harrison S; Cunningham R; Baxter D; Kaczmarski E; Maclennan J; Cameron JC; Stuart JM
J Infect Dis; 2008 Mar; 197(5):737-43. PubMed ID: 18271745
[TBL] [Abstract][Full Text] [Related]
7. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.
Wang X; Shutt KA; Vuong JT; Cohn A; MacNeil J; Schmink S; Plikaytis B; Messonnier NE; Harrison LH; Clark TA; Mayer LW
J Infect Dis; 2015 Jun; 211(12):1887-94. PubMed ID: 25556253
[TBL] [Abstract][Full Text] [Related]
8. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
[TBL] [Abstract][Full Text] [Related]
9. Serogroup A meningococcal conjugate vaccines in Africa.
Kristiansen PA; Jørgensen HJ; Caugant DA
Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
[TBL] [Abstract][Full Text] [Related]
10. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study.
Campbell H; Andrews N; Parikh SR; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME; Ladhani SN
Lancet Child Adolesc Health; 2022 Feb; 6(2):96-105. PubMed ID: 34883094
[TBL] [Abstract][Full Text] [Related]
11. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
12. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
[TBL] [Abstract][Full Text] [Related]
13. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
[TBL] [Abstract][Full Text] [Related]
14. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
[TBL] [Abstract][Full Text] [Related]
15. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.
Campbell H; Andrews N; Borrow R; Trotter C; Miller E
Clin Vaccine Immunol; 2010 May; 17(5):840-7. PubMed ID: 20219881
[TBL] [Abstract][Full Text] [Related]
16. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
Trotter CL; Gay NJ; Edmunds WJ
Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
[TBL] [Abstract][Full Text] [Related]
17. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
Larrauri A; Cano R; García M; Mateo Sd
Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
[TBL] [Abstract][Full Text] [Related]
18. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal vaccines: current issues and future strategies.
Cohn AC; Harrison LH
Drugs; 2013 Jul; 73(11):1147-55. PubMed ID: 23839656
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
